Filing Details
- Accession Number:
- 0001104659-23-126424
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-12-15 16:31:42
- Reporting Period:
- 2023-12-13
- Accepted Time:
- 2023-12-15 16:31:42
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1175151 | Cytosorbents Corp | CTSO | Surgical & Medical Instruments & Apparatus (3841) | 980373793 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1920967 | Jiny Kim | C/O Cytosorbents Corporation 305 College Road East Princeton NJ 08540 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2023-12-13 | 7,519 | $1.33 | 77,819 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Common Stock Warrant (Right to Buy) | Acquisiton | 2023-12-13 | 2,631 | $0.00 | 2,631 | $2.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
2,631 | 2023-12-13 | 2028-12-13 | No | 4 | P | Direct |
Footnotes
- These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant.
- Includes (a) 69,300 restricted stock units ("RSUs") granted on April 1, 2022 that will be settled into shares of Common Stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan") and (b) 8,519 shares of Common Stock owned by the reporting person.